Alpha-Synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway

Journal of Neuroscience Research

Volumn 88, Issue 8, 2010, Pages 1764-1776

  Wu, Nanping ^a   Joshi, Prasad R ^a   Cepeda, Carlos ^a   Masliah, Eliezer ^b   Levine, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Glutamate receptors; Parkinson's disease; Postsynaptic currents

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALPHA SYNUCLEIN; AMPA RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TETRODOTOXIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CELL KINETICS; CONTROLLED STUDY; CORPUS STRIATUM; CORTICOSTRIATAL SYNAPSE; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; GABAERGIC TRANSMISSION; GENE OVEREXPRESSION; MALE; MEDIUM SIZED SPINY NEURON; MOUSE; NERVE CELL; NERVE POTENTIAL; NEUROTRANSMITTER RELEASE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SYNAPTIC TRANSMISSION;

6-CYANO-7-NITROQUINOXALINE-2,3-DIONE; AGE FACTORS; ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, NEWBORN; BICUCULLINE; BIOPHYSICS; CEREBRAL CORTEX; CORPUS STRIATUM; ELECTRIC STIMULATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GABA ANTAGONISTS; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEURAL PATHWAYS; NEURONS; PATCH-CLAMP TECHNIQUES; PICROTOXIN; SODIUM CHANNEL BLOCKERS; SYNAPTIC POTENTIALS; TETRODOTOXIN;

EID: 77952327983     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22327     Document Type: Article

References (50)

1. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A. 2000. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25:239-252. (Pubitemid 30316525)
2. Bamford NS, Zhang H, Schmitz Y, Wu NP, Cepeda C, Levine MS, Schmauss C, Zakharenko SS, Zablow L, Sulzer D. 2004. Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals. Neuron 42:653-663. (Pubitemid 38639883)
3. + currents in acutely isolated, adult rat neostriatal neurons. J Neurosci 14:6667-6686.
4. Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL. 2002. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22:8797-8807. (Pubitemid 35379049)
5. Calabresi P, Mercuri NB, Sancesario G, Bernardi G. 1993. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 116:433-452.
6. Cepeda C, Walsh JP, Hull CD, Howard SG, Buchwald NA, Levine MS. 1989. Dye-coupling in the neostriatum of the rat: I. Modulation by dopamine-depleting lesions. Synapse 4:229-237.
7. Cepeda C, Colwell CS, Itri JN, Chandler SH, Levine MS. 1998. Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J Neurophysiol 79:82-94. (Pubitemid 28133801)
8. Cepeda C, Hurst RS, Altemus KL, Flores-Hernandez J, Calvert CR, Jokel ES, Grandy DK, Low MJ, Rubinstein M, Ariano MA, Levine MS. 2001. Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor-deficient mice. J Neurophysiol 85:659-670. (Pubitemid 32147768)
9. Cepeda C, Hurst RS, Calvert CR, Hernandez-Echeagaray E, Nguyen OK, Jocoy E, Christian LJ, Ariano MA, Levine MS. 2003. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 23:961-969. (Pubitemid 36206187)
10. Cepeda C, Wu N, Andre VM, Cummings DM, Levine MS. 2007. The corticostriatal pathway in Huntington's disease. Prog Neurobiol 81:253-271.
11. Cepeda C, Andre VM, Yamazaki I, Wu N, Kleiman-Weiner M, Levine MS. 2008. Differential electrophysiological properties of dopamine D1 and D2 receptor-containing striatal medium-sized spiny neurons. Eur J Neurosci 27:671-682. (Pubitemid 351239295)
12. Chesselet MF. 2008. In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? Exp Neurol 209:22-27.
13. Czubayko U, Plenz D. 2002. Fast synaptic transmission between striatal spiny projection neurons. Proc Natl Acad Sci USA 99:15764-15769. (Pubitemid 35404004)
14. Dauer W, Przedborski S. 2003. Parkinson's disease: mechanisms and models. Neuron 39:889-909.
15. Fernagut PO, Chesselet MF. 2004. Alpha-synuclein and transgenic mouse models. Neurobiol Dis 17:123-130.
16. Fernagut PO, Hutson CB, Fleming SM, Tetreaut NA, Salcedo J, Masliah E, Chesselet MF. 2007. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse 61:991-1001. (Pubitemid 350271779)
17. Fleming SM, Salcedo J, Fernagut PO, Rockenstein E, Masliah E, Levine MS, Chesselet MF. 2004. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 24:9434-9440. (Pubitemid 39426179)
18. Fleming SM, Fernagut PO, Chesselet MF. 2005. Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx 2:495-503. (Pubitemid 41444883)
19. Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, Chesselet MF. 2008. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci 28:247-256.
20. Fonnum F, Soreide A, Kvale I, Walker J, Walaas I. 1981a. Glutamate in cortical fibers. Adv Biochem Psychopharmacol 27:29-41.
21. Fonnum F, Storm-Mathisen J, Divac I. 1981b. Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain. Neuroscience 6:863-873. (Pubitemid 11101763)
22. Galarraga E, Bargas J, Martinez-Fong D, Aceves J. 1987. Spontaneous synaptic potentials in dopamine-denervated neostriatal neurons. Neurosci Lett 81:351-355. (Pubitemid 17159523)
23. George JM, Jin H, Woods WS, Clayton DF. 1995. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15:361-372.
24. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ, Gajendiran M, Roth BL, Chesselet MF, Maidment NT, Levine MS, Shen J. 2003. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278:43628-43635. (Pubitemid 37345989)
25. Gureviciene I, Gurevicius K, Tanila H. 2007. Role of alpha-synuclein in synaptic glutamate release. Neurobiol Dis 28:83-89. (Pubitemid 47429976)
26. Halliday GM, Del Tredici K, Braak H. 2006. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease. J Neural Transm Suppl 70:99-103. (Pubitemid 44622185)
27. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T. 1995. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14:467-475.
28. Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, Chesselet MF, Levine MS. 2001. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol 86:2667-2677. (Pubitemid 33139038)
29. Koos T, Tepper JM. 1999. Inhibitory control of neostriatal projection neurons by GABAergic interneurons. Nat Neurosci 2:467-472. (Pubitemid 30491258)
30. Koos T, Tepper JM, Wilson CJ. 2004. Comparison of IPSCs evoked by spiny and fast-spiking neurons in the neostriatum. J Neurosci 24:7916-7922. (Pubitemid 39215696)
31. Larsen KE, Schmitz Y, Troyer MD, Mosharov E, Dietrich P, Quazi AZ, Savalle M, Nemani V, Chaudhry FA, Edwards RH, Stefanis L, Sulzer D. 2006. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 26:11915-11922. (Pubitemid 44772102)
32. Liu S, Ninan I, Antonova I, Battaglia F, Trinchese F, Narasanna A, Kolodilov N, Dauer W, Hawkins RD, Arancio O. 2004. Alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J 23:4506-4516. (Pubitemid 39601975)
33. Maidment NT, Lam HA, Ackerson LC, Rockenstein E, Masliah E. 2006.Dysregulation of dopamine transmission in mice overexpressing human wildtype alpha-synuclein. Society for Neuroscience Abstracts Program No. 378.374.
34. Meredith GE, Sonsalla PK, Chesselet MF. 2008. Animal models of Parkinson's disease progression. Acta Neuropathol 115:385-398.
35. Oertel WH, Mugnaini E. 1984. Immunocytochemical studies of GABAergic neurons in rat basal ganglia and their relations to other neuronal systems. Neurosci Lett 47:233-238. (Pubitemid 14081892)
36. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047. (Pubitemid 27443610)
37. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E. 2002. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 68:568-578. (Pubitemid 34575622)
38. Sidhu A, Wersinger C, Vernier P. 2004. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J 18:637-647.
39. Smith AD, Bolam JP. 1990. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci 13:259-265.
40. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. 1997. Alpha-synuclein in Lewy bodies. Nature 388:839-840.
41. Springer W, Kahle PJ. 2006. Mechanisms and models of alpha-synuclein- related neurodegeneration. Curr Neurol Neurosci Rep 6:432-436.
42. Starling AJ, Andre VM, Cepeda C, de Lima M, Chandler SH, Evine MS. 2005. Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J Neurosci Res 82:377-386. (Pubitemid 41552488)
43. Totterdell S, Meredith GE. 2005. Localization of alpha-synuclein to identified fibers and synapses in the normal mouse brain. Neuroscience 135:907-913. (Pubitemid 41407753)
44. Trojanowski JQ, Lee VM. 1998. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies:implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 55:151-152. (Pubitemid 28110056)
45. Venance L, Glowinski J, Giaume C. 2004. Electrical and chemical transmission between striatal GABAergic output neurones in rat brain slices. J Physiol 559:215-230. (Pubitemid 39206964)
46. Wang L, Fleming SM, Chesselet MF, Tache Y. 2008. Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. Neuroreport 19:873-876. (Pubitemid 351655158)
47. Watson JB, Hatami A, David H, Masliah E, Roberts K, Evans CE, Levine MS. 2009. Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. Neuroscience 159:501-513.
48. Wersinger C, Prou D, Vernier P, Sidhu A. 2003. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J 17:2151-2153.
49. Yavich L, Tanila H, Vepsalainen S, Jakala P. 2004. Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci 24:11165-11170. (Pubitemid 40012976)
50. Zucker RS, Regehr WG. 2002. Short-term synaptic plasticity. Annu Rev Physiol 64:355-405.